Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 2401 - 2408 of 12085 results
Georgetown Varsity Blues Dad Wins by Revealing Rich Kid Perks
June 27, 2022| News
Group Health Plans in the Crossfire: Facilitating Reproductive Choice in the Wake of Dobbs v. Jackson Women’s Health
June 26, 2022| Blog| Viewpoint
HIPAA Won’t Protect You If Prosecutors Want Your Reproductive Health Records
June 24, 2022| News
DOJ and FTC Virtual Workshop: Agencies Discuss Novel Approaches to Address Competition Issues in Pharmaceutical Mergers
June 23, 2022| Blog| Viewpoint
Patent Dealmaking- High-level Insights Into The Patent Deals Marketplace
June 23, 2022| News
What Would the American Data Privacy and Protection Act Mean for the Health Industry?
June 23, 2022| Blog| Viewpoint
News of Recent Layoffs Prompts a Review of the WARN Act: What’s Changed Since 2020?
June 22, 2022| Blog| Viewpoint
Avoiding Unforced Tech DI Errors At The ITC
June 22, 2022| News
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|